Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial

BACKGROUND: Patients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS). CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Yumin, Xu, Yang, Tian, Hui, Jiang, Sizhu, Jiang, Guofang, Li, Puqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013811/
https://www.ncbi.nlm.nih.gov/pubmed/35445052
http://dx.doi.org/10.3389/fmed.2022.783387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013811/
https://www.ncbi.nlm.nih.gov/pubmed/35445052
http://dx.doi.org/10.3389/fmed.2022.783387

Ejemplares similares